BioSpace News Archive

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”) today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2022.

ImmunoGen, Inc. announced that on March 31, 2023, the Compensation Committee of the Company’s Board of Directors approved, in aggregate, grants of non-qualified stock option awards to purchase 106,600 shares of its common stock and restricted stock units covering 7,800 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.

Viking Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,586,300 additional shares of common stock.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

MedMira Inc., reported on its financial results for the quarter ended January 31, 2023.

Research from Florida International University’s College of Business (FIU Business) found that a machine learning (ML) algorithm that uses hospital data and social determinants of health data can help diagnose a stroke quickly – before the results of laboratory tests or diagnostic images are available – with 83 percent accuracy.

Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer’s Drug Discovery Foundation announce a joint request for proposal for the 2023 ADDF-Harrington Scholar Award.

StageZero Life Sciences (TSX: SZLS) (“StageZero” or the “Company”), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions

Today, the U.S. Food and Drug Administration announced it is requiring manufacturers of opioid analgesics dispensed in outpatient settings to make prepaid mail-back envelopes available to outpatient pharmacies and other dispensers as an additional opioid analgesic disposal option for patients.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on April 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 7 individuals hired by Acutus in March 2023.